NEW YORK – SomaLogic said Thursday it has launched its SomaSignal Proteomics for Precision Medicine Initiative, which aims to lay the groundwork for clinical use of its SomaSignal proteomic tests.
The initiative aims to enable healthcare providers to use proteomic technology to make decisions at the point of care based on a patient's individual proteome signature, said Boulder, Colorado-based SomaLogic.
The company is launching clinical trials in areas including type 2 diabetes, cardiovascular disease, and cancer with Emory University, Intermountain Healthcare, CommonSpirit Health and UCHealth — a network of 12 hospitals and hundreds of physicians across Colorado, southern Wyoming, and western Nebraska — that will evaluate the usefulness of its SomaSignal tests in clinical practice.
The healthcare providers will use the tests to help assess patient health status and disease risk and also guide patient management. They will also evaluate whether use of the SomaSignal tests motivates patients to be more actively involved in their care.
The SomaSignal tests use SomaLogic's aptamer-based affinity reagents called Somamers to measure proteins in patient samples. The company launched its first SomaSignal tests in 2019, offering them at several Colorado doctors' practices. It currently offers 12 tests as laboratory-developed tests for indications including risk of major cardiovascular events in patients with and without known heart disease and the presence of excess liver fat.
"We’re excited to work with these clinical innovators who see the value of proteomics as a tool for precision medicine and medical management," Angela Bakker-Lee, SomaLogic’s executive VP for healthcare markets, said in a statement. "SomaLogic has one of the largest proprietary clinical proteomics databases and it drives our diagnostic models for addressing cardiovascular disease and other chronic conditions. We look forward to demonstrating the impact our tests can have on improving outcomes and lowering the total cost of care."